

**FOR IMMEDIATE RELEASE**

**Tissue Regeneration Systems Adds Business Development Executive**

**Plymouth, MI, January 14, 2015** – Tissue Regeneration Systems, Inc. ("TRS") today announced that Sharon Schulzki has joined the company as Senior Vice President of Business Development. Prior to joining TRS, Schulzki served as Vice President of Surgical Affairs for Depuy Synthes Spine, a division of Johnson & Johnson Corporation. She was the Chief Operating Officer of NSpine, a start-up medical device company acquired by Synthes in 2007. Prior to that, Schulzki served as Chief Operating Officer of MacroPore Biosurgery, and Vice President of Marketing for the Howmedica division of Pfizer Corporation.

“Sharon has an impressive track record of building successful companies in the orthopedics, spine, and biomaterials spaces and we are delighted to have her join our senior management team,” said Jim Fitzsimmons, president and chief executive officer. “She brings an essential skill set to TRS as we execute our business plan of forging corporate partnerships around our novel technology platform,” he added.

In August, 2013 TRS announced that it received clearance from the U.S. Food and Drug Administration for a cranial implant incorporating the company's bioresorbable, mineral coated, scaffold technology platform for skeletal reconstruction and bone regeneration. This was the first FDA clearance of such an implant fabricated by means of 3D printing. In June, 2014 the Johnson and Johnson Innovation Center announced the formation of a strategic collaboration with TRS and DePuy Synthes Trauma to develop patient-specific, bioresorbable, osteoconductive implants for large bone segmental defect treatment in trauma and orthopedic oncology. In August, 2014 TRS opened its new, GMP compliant fabrication facility in Plymouth, Michigan. “The company has made tremendous progress over the last eighteen months,” said Fitzsimmons.

“The TRS technology platform has broad applicability and enables the development of novel products addressing several large medical markets,” said Sharon Schulzki. “I look forward to helping TRS establish corporate partnerships to create and commercialize these products,” she added.

**About Tissue Regeneration Systems**

Founded in 2007 with principal operations in Plymouth, Michigan, Tissue Regeneration Systems is an early-stage medical device company commercializing a breakthrough skeletal reconstruction and bone regeneration technology platform developed from ground breaking research conducted at the Universities of Michigan and Wisconsin. To learn more about TRS, visit the company's website at [www.tissuesys.com](http://www.tissuesys.com).

###

**Press Contact:**

Jim Fitzsimmons  
President and Chief Executive Officer  
Tissue Regeneration Systems, Inc.  
(206) 489-5110  
[jim@tissuesys.com](mailto:jim@tissuesys.com)